Nestlé Moves Further Into Health, Buying Peanut-Allergy Treatment Maker
Swiss giant agrees to purchase Aimmune in deal valuing the company at $2.6 billion, including debt
✒ Aimmune focuses on food allergy treatment and is currently 25% owned by Nestlé. Nestlé will acquire the outstanding shares it does not already own in this all-cash offer, marking its biggest bet yet on health science.
This deal takes Nestlé boss Ulf Mark Schneider back into familiar territory. He used to be the CEO of Fresenius for 13 years before joining Nestlé in 2017.